- Trials with a EudraCT protocol (815)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
815 result(s) found for: prostate cancer.
Displaying page 8 of 41.
EudraCT Number: 2019-002000-41 | Sponsor Protocol Number: IRST185.07 | Start Date*: 2019-11-20 | |||||||||||
Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS | |||||||||||||
Full Title: Experimental study to evaluate the impact of 18F-PSMA PET / CT in the management of patients with prostate cancer. | |||||||||||||
Medical condition: Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006014-14 | Sponsor Protocol Number: AMW/003/C | Start Date*: 2012-04-27 | |||||||||||
Sponsor Name:AMW GmbH | |||||||||||||
Full Title: An open label, multiple dose Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy and safety of a new GnRH implant (AMW Leuprorelin 10.72 mg implant) appl... | |||||||||||||
Medical condition: prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021529-11 | Sponsor Protocol Number: EMR62242-006 | Start Date*: 2011-03-10 | ||||||||||||||||
Sponsor Name:Merck KGaA | ||||||||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicenter Phase II trial investigating two doses of EMD 525797 in subjects with asymptomatic or mildly symptomatic metastatic castrate-resistant pr... | ||||||||||||||||||
Medical condition: subjects with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (mCRPC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) NL (Completed) ES (Prematurely Ended) SK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004627-12 | Sponsor Protocol Number: CABASEM-SOGUG | Start Date*: 2011-12-22 | ||||||||||||||||
Sponsor Name:SOGUG - Spanish Oncology Genitourinary Group | ||||||||||||||||||
Full Title: Phase II Study of Weekly Cabazitaxel for Advanced Prostate Cancer in "Unfit" Hormone-Refractory Patients Previously Treated with Docetaxel. | ||||||||||||||||||
Medical condition: Advanced Prostate Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003382-18 | Sponsor Protocol Number: BED-PSMA-302 | Start Date*: 2020-05-25 | |||||||||||
Sponsor Name:Blue Earth Diagnostics Ireland Ltd. | |||||||||||||
Full Title: A prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with suspected prostate cancer recurrence b... | |||||||||||||
Medical condition: Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FI (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002203-32 | Sponsor Protocol Number: XRP6976J/3501 | Start Date*: 2006-02-15 | |||||||||||
Sponsor Name:sanofi-aventis group | |||||||||||||
Full Title: A Multicenter, Open-Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD®- leuprolide acetate) in Combination with TAXOTERE® (docetaxel) Administered Every Thre... | |||||||||||||
Medical condition: Prostate Cancer at High Risk of Relapse After Radical Prostatectomy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) BE (Completed) GB (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001279-35 | Sponsor Protocol Number: 8-55-52014-200 | Start Date*: 2012-09-13 | |||||||||||
Sponsor Name:Ipsen Pharma S.A.S | |||||||||||||
Full Title: A phase III single arm study to evaluate the efficacy, safety and local tolerability of a subcutaneous 3‑month formulation of triptorelin pamoate (11.25 mg) in patients with locally advanced or met... | |||||||||||||
Medical condition: Locally advanced or metastatic prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: LV (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014839-21 | Sponsor Protocol Number: 2008-CaP-FCH | Start Date*: 2009-10-09 | |||||||||||
Sponsor Name:CIS bio international, member of IBA group | |||||||||||||
Full Title: Diagnostic value of 18F-choline PET/CT for the detection of systemic prostate cancer disease. | |||||||||||||
Medical condition: de novo patients with histologically confirmed prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003118-42 | Sponsor Protocol Number: BAY88-8223/16507 | Start Date*: 2014-08-08 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A three arm randomized, open-label Phase II study of radium-223 dichloride 50 kBq/kg (55 kBq/kg after implementation of NIST update) versus 80 kBq/kg (88 kBq/kg after implementation of NIST update)... | |||||||||||||
Medical condition: Castration resistant prostate cancer with bone metastasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) CZ (Completed) SE (Completed) FI (Completed) ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004338-26 | Sponsor Protocol Number: FE200486 CS28 | Start Date*: 2008-11-18 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: Ensayo clínico abierto, aleatorizado, de grupos paralelos que compara degarelix frente a bloqueo androgénico combinado (goserelina + bicalutamida) en términos de reducción de la puntuación en la es... | |||||||||||||
Medical condition: Cáncer de próstata | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: ES (Completed) GB (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003809-26 | Sponsor Protocol Number: SP010 | Start Date*: 2013-12-04 | |||||||||||
Sponsor Name:SOTIO a.s. | |||||||||||||
Full Title: Open-label, one-arm, multi-centre phase II clinical trial with second cycle of active cellular immunotherapy DCVAC/PCa in patients with localized prostate cancer after primary radical prostatectomy... | |||||||||||||
Medical condition: Localized prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-006063-28 | Sponsor Protocol Number: SHR3162-III-305 | Start Date*: 2021-10-07 | |||||||||||||||||||||
Sponsor Name:Jiangsu Hengrui Medicine Co., Ltd | |||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Placebo Combined with AA-P as First-Line Tr... | |||||||||||||||||||||||
Medical condition: Metastatic Castration-Resistant Prostate Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001784-13 | Sponsor Protocol Number: ISRCTN91422391 | Start Date*: 2014-12-29 | |||||||||||
Sponsor Name:Queen Mary University of London | |||||||||||||
Full Title: PROVENT: A randomised, double blind, placebo controlled feasibility study to examine the clinical effectiveness of aspirin and/or Vitamin D3 to prevent disease progression in men on active surveill... | |||||||||||||
Medical condition: Prostate cancer disease progression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003381-40 | Sponsor Protocol Number: BED-PSMA-301 | Start Date*: 2020-06-22 | |||||||||||
Sponsor Name:Blue Earth Diagnostics Ireland Ltd. | |||||||||||||
Full Title: A prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with newly diagnosed prostate cancer | |||||||||||||
Medical condition: Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) FI (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000469-13 | Sponsor Protocol Number: FJ-228-0007 | Start Date*: 2006-03-10 | |||||||||||
Sponsor Name:Gloucester Pharmaceuticals Inc. | |||||||||||||
Full Title: A MULTICENTER, OPEN-LABEL CONTINUATION TRIAL EVALUATING THE TOLERABILITY AND ACTIVITY OF DEPSIPEPTIDE (FK228) IN PATIENTS THAT HAVE COMPLETED A PRIOR CLINICAL STUDY WITH DEPSIPEPTIDE | |||||||||||||
Medical condition: Refractory Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004567-29 | Sponsor Protocol Number: RADSIN1 | Start Date*: 2004-11-22 | |||||||||||
Sponsor Name:IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO | |||||||||||||
Full Title: Pelvic lymph node metastases from bladder and prostate cancer magnetic resonance imaging with ultrasmall superparamagnetic iron oxyde sinerem. | |||||||||||||
Medical condition: SUSPECT LYMPHONODAL METASTASES | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002014-13 | Sponsor Protocol Number: MAdCaP2013 | Start Date*: 2014-03-05 | |||||||||||
Sponsor Name:NHS greater Glasgow and Clyde [...] | |||||||||||||
Full Title: A phase I/randomised phase II trial of abiraterone acetate with or without RO5503781 / idasanutlin in patients with metastatic castration resistant prostate cancer who have not previously receiv... | |||||||||||||
Medical condition: Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004210-28 | Sponsor Protocol Number: I-1315 | Start Date*: 2015-01-29 | |||||||||||||||||||||
Sponsor Name:Department of Nuclear Medicine, Aalborg University Hospital | |||||||||||||||||||||||
Full Title: 68Ga-PSMA PET/CT vs. MRI/CT vs. lymphadenectomy for the identification of lymph node metastases in locally advanced prostate cancer patients: a diagnostic test accuracy study | |||||||||||||||||||||||
Medical condition: Patients diagnosed with advanced prostate cancer that are scheduled for lymph node staging. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002071-29 | Sponsor Protocol Number: ITT012“ELISA” | Start Date*: 2014-12-22 | |||||||||||
Sponsor Name:DIPARTIMENTO DI ONCOLOGIA MEDICA USL8 | |||||||||||||
Full Title: A RANDOMIZED PROSPECTIVE MULTICENTRE PHASE II STUDY OF ANDROGEN DEPRIVATION THERAPY (ADT) PLUS RADIOTHERAPY WITH OR WITHOUT ABIRATERONE ACETATE AND PREDNISONE IN LOCALLY ADVANCED VERY HIGH-RISK PRO... | |||||||||||||
Medical condition: LOCALLY ADVANCED VERY HIGH-RISK PROSTATE CANCER | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004310-18 | Sponsor Protocol Number: SPL-01-001 | Start Date*: 2019-10-07 | |||||||||||
Sponsor Name:Saving Patients' Lives Medical B.V. | |||||||||||||
Full Title: A confirmatory, prospective, open-label, single-arm, reader-blinded multi-centre phase 3 study to assess the diagnostic accuracy of Ferumoxtran-10-enhanced Magnetic Resonance Imaging (MRI) and unen... | |||||||||||||
Medical condition: newly-diagnosed prostate cancer (PCA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
